Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. (ZYME) is a clinical-stage biotechnology leader developing innovative bispecific antibodies and antibody-drug conjugates for oncology and autoimmune diseases. This page serves as the definitive source for ZYME news, providing investors and industry professionals with timely updates on therapeutic advancements and corporate developments.
Access consolidated updates including clinical trial milestones, regulatory filings, strategic partnerships, and financial results. Our curated collection features official press releases and verified news about ZYME's proprietary platforms like Azymetric™ and Albucore™, alongside collaborations with global biopharma leaders.
Key content categories include progress reports on novel cancer therapies, licensing agreements, scientific presentations, and pipeline expansion announcements. All materials maintain strict factual accuracy while avoiding speculative analysis to support informed decision-making.
Bookmark this page for efficient tracking of ZYME's advancements in multifunctional biotherapeutics. Check regularly for updates on their pioneering work in antibody engineering and targeted cancer treatment solutions.
Zymeworks Inc. (NYSE: ZYME) has initiated an underwritten public offering of its common shares and pre-funded warrants. The offering is contingent on market conditions, and there is no guarantee of completion. Zymeworks will provide underwriters a 30-day option to purchase an additional 15% of shares offered. Jefferies, Evercore ISI, Stifel, and Wells Fargo Securities are acting as joint managers of the offering. A shelf registration statement was previously filed with the SEC. No securities will be offered in Canada, and the offering is made solely through a prospectus.
Zymeworks Inc. (NYSE: ZYME) announced strategic priorities for 2022-2023 under new Chair and CEO Kenneth Galbraith. Key initiatives include completing pivotal studies for zanidatamab, optimizing R&D strategies, and establishing partnerships to enhance growth. The company aims to streamline operations, reducing workforce by at least 25% to cut costs. Cash reserves are approximately $250 million, expected to fund operations into late 2022. Zymeworks anticipates key clinical data releases and plans to improve its financial position through collaborations and potential fundraising.
Zymeworks Inc. (NYSE: ZYME) announced an equity inducement award for Kenneth Galbraith, its new Chair, President, and CEO, in compliance with NYSE Rule 303A.08. Galbraith was granted a stock option to purchase 500,000 shares at an exercise price of $14.97, effective from his start date on January 15, 2022. The options will vest over four years, with accelerated vesting upon termination without cause or in case of death/disability. This grant was made outside the current stock option plan but will align with similar terms.
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, announced that
Zymeworks focuses on developing next-generation multifunctional biotherapeutics, including its lead candidate, zanidatamab, for HER2-expressing solid tumors.
Zymeworks Inc. (NYSE: ZYME) announced the appointment of Kenneth Galbraith as Chair and CEO, effective by February 1, 2022. Galbraith, an experienced leader in life sciences, succeeds co-founder Ali Tehrani, who will transition to an advisory role. Neil Klompas has been promoted to both CFO and COO. The Board believes Galbraith's leadership is pivotal for advancing the development of zanidatamab and expanding the R&D pipeline. Zymeworks aims to progress pivotal clinical studies for zanidatamab this year, demonstrating its commitment to innovative cancer therapies.
Zymeworks announced that BeiGene has dosed the first patient in South Korea for the HERIZON-GEA-01 trial, part of their collaboration agreement. This milestone triggers an $8 million payment to Zymeworks. The HERIZON-GEA-01 trial aims to enroll approximately 700 patients across 300 sites globally, with a 24-month enrollment period. Success in this trial could lead to a supplemental Biologics License Application submission in the U.S. as early as 2024.
Zymeworks Inc. (NYSE: ZYME) announced promising clinical trial results for zanidatamab, a HER2-targeted bispecific antibody, at the San Antonio Breast Cancer Symposium. In a study of 24 patients with heavily pretreated HER2-positive breast cancer, the overall confirmed objective response rate was 36.4%, with a disease control rate of 86.4%. The median progression-free survival reached 7.3 months. The results indicate that zanidatamab combined with chemotherapy could offer a new treatment avenue for patients after multiple prior therapies.
Zymeworks Inc. (NYSE: ZYME) announced that Janssen Biotech has dosed the first patient with JNJ-78306358, a bispecific antibody developed using Zymeworks' proprietary platforms. This marks the second bispecific program from Janssen to enter clinical trials in 2023. Zymeworks will receive milestone payments as part of a licensing agreement, which includes an upfront payment of US$50 million and potential milestones totaling US$1.4 billion. The Azymetric™ and EFECT™ platforms enhance the efficacy of therapeutics and are pivotal to Zymeworks' drug development efforts.
Zymeworks Inc. (NYSE: ZYME) has announced new clinical data on zanidatamab, a HER2-targeted bispecific antibody, showing encouraging results in heavily pretreated HER2-positive breast cancer patients. The drug, administered with chemotherapy, yielded a confirmed objective response rate of 37.5% and a disease control rate of 81.3% in 16 evaluable patients. The updated data will be presented at the SABCS conference from December 7-10, 2021. Zymeworks is progressing zanidatamab through multiple clinical trials and holds Breakthrough Therapy designation from the FDA for specific cancer indications.
Zymeworks Inc. (NYSE: ZYME) announced that Neil Josephson, M.D., will transition from interim Chief Medical Officer to permanent CMO on November 15, 2021. Dr. Josephson has led Zymeworks’ medical organization since May and is tasked with advancing the clinical pipeline, including the pivotal trial enrollment for zanidatamab in treating HER2-positive gastroesophageal adenocarcinomas. Zymeworks focuses on developing multifunctional biotherapeutics, with zanidatamab and ZW49 as its lead candidates, while expanding its preclinical pipeline and strategic partnerships.
FAQ
What is the current stock price of Zymeworks (ZYME)?
What is the market cap of Zymeworks (ZYME)?
